Comparative Pharmacology
Head-to-head clinical analysis: DISOBROM versus KETOTIFEN FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DISOBROM versus KETOTIFEN FUMARATE.
DISOBROM vs KETOTIFEN FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DISOBROM is a synthetic compound that acts as a partial agonist at benzodiazepine sites on GABAA receptors, potentiating GABAergic neurotransmission. It also exhibits antagonistic activity at peripheral benzodiazepine receptors (TSPO).
Antihistamine and mast cell stabilizer; inhibits release of histamine and other mediators from mast cells; also blocks histamine H1 receptors.
DISOBROM is not a recognized drug. Please verify the name.
1 mg orally twice daily; ophthalmic: 1 drop in each eye every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 12-24 hours (mean 18 hours); requires twice-daily dosing after initial titration.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (20-30%); fecal excretion accounts for <10%.
Renal (50-70% as conjugates, <2% unchanged), fecal (<10%), with enterohepatic circulation.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine / Mast Cell Stabilizer